Only 1 in 3 patients will achieve remission on their first antidepressant, and 67% of patients require 4 antidepressant trials before symptoms remit, said Thomas L. Schwartz, MD, during a session on strategies for switching, combining, or augmenting treatments for patients with major depressive disorder.
Only 1 in 3 patients will achieve remission on their first antidepressant, and 67% of patients require 4 antidepressant trials before symptoms remit, said Thomas L. Schwartz, MD, professor and vice chair, Department of Psychiatry, SUNY Upstate Medical University.
In a session at the 2017 Neuroscience Education Institute Congress in Colorado Springs, Colorado, Schwartz gave an informational session on strategies for switching, combining, or augmenting treatments for patients with major depressive disorder (MDD).
First, Schwartz explained what to look for when choosing the initial antidepressant. It is important to look at the comparable efficiency between and within classes of medications, and the initial selection of antidepressant is largely based on: anticipated side effects, safety/tolerability for individual patients, patient preference, medication response in prior episodes, and cost.
Then, Schwartz outlined factors to consider when choosing between switching or augmenting treatment. A physician should consider switching to a different antidepressant when:
There are several techniques for switching treatments, Schwartz said:
There is no evidence to support preference for one agent or class over another, and switching within the same class or to another class are both options, said Schwartz. The most commonly used treatments when switching are other selective serotonin reuptake inhibitors (SSRIs)/serotonin and norepinephrine reuptake inhibitors (SNRIs), bupropion, and mirtazapine. Underused treatments include tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs).
“Withdrawal symptoms can generally begin within hours to days of dose reduction,” said Schwartz.
Withdrawing SSRIs and SNRIs typically cause flu-like symptoms such as nausea, lethargy, and irritability, said Schwartz. Venlafaxine is associated with the most severe withdrawal effects, meanwhile fluoxetine rarely causes withdrawal symptoms due to the long half-life of the parent drug and its active metabolite. Paroxetine withdrawal effects can be more common or more severe with paroxetine than with some other SSRIs.
Closing the session, Schwartz explained that a physician should consider an adjunctive medication when:
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More